Business Context and Reporting Period
Company: H.B. Fuller Company (H.B. Fuller)
Filing Type: Form 8-K (Current Report)
Date of Report: June 25, 2026
Event: Entry into a Material Definitive Agreement to acquire Advanced Medical Solutions Group plc ("AMS") via a recommended cash offer. The transaction is structured as a court-sanctioned scheme of arrangement under UK law, with an option to convert to a takeover offer.
Key Financial Metrics and Transaction Terms
Transaction Consideration: 285 pence in cash per AMS share.
Financing Arrangements (Bridge Credit Agreements):
- Secured Bridge Credit Agreement: Up to $2,086,713,188 available. Interest rate: Index + 0.75% or 1.75% (with 0.25% increases every 90 days). Matures 364 days post-closing.
- Unsecured Bridge Credit Agreement: Up to $917,000,000 available. Interest rate: Index + 1.50% or 2.50% (with 0.25% increases every 90 days). Matures 364 days post-closing.
- Administrative Agent: Goldman Sachs Bank USA.
- Currency: Borrowings in USD may be converted to GBP via foreign exchange forward transactions to fund the cash consideration.
Irrevocable Undertakings: AMS Board members holding approximately 0.34% of outstanding shares (745,766 shares) have agreed to vote in favor of the scheme.
Financial Performance Metrics: The filing text does not provide specific revenue, profit, cash flow, margin, or existing debt figures for H.B. Fuller or AMS. This report focuses solely on the transaction structure and financing.
Material Changes and Conditions
The filing announces a material change in corporate structure through the proposed acquisition of AMS. The transaction is subject to the following key conditions:
- Approval by a majority in number of AMS shareholders representing at least 75% in value of shares present and voting.
- Sanction by the High Court of Justice in England and Wales.
- Receipt of necessary regulatory approvals.
- Completion of the scheme by the "Long-Stop Date" of June 25, 2027.
Expected Completion: End of calendar year 2026, subject to satisfaction or waiver of conditions.
Guidance, Outlook, and Risks
Management Commentary: The Company and AMS have entered into a Co-operation Agreement to use reasonable endeavors to secure approvals and prepare offering documents to meet the Long-Stop Date.
Risks and Contingencies: The filing includes extensive forward-looking statement disclaimers. Key risks include:
- Failure to obtain requisite regulatory or shareholder approvals.
- Changes in global economic, political, or market conditions.
- Disruptions to business operations during integration.
- Failure to realize anticipated synergies.
- Fluctuations in exchange and interest rates.
- Legal, environmental, and safety compliance risks.
Unusual Items: The financing includes specific "draw-stop" triggers and restrictions on lenders' ability to cancel commitments for eight weeks after the Long-Stop Date to ensure funding availability.
Investor Verification Checklist
- Verify the total transaction value based on the 285 pence per share offer and AMS's current share count.
- Confirm the status of regulatory approvals required in the UK and other jurisdictions where AMS operates.
- Review the full text of the Co-operation Agreement (Exhibit 2.2) and Bridge Credit Agreements (Exhibits 10.2 and 10.3) for specific covenants and fees.
- Monitor the timeline for the AMS shareholders' meeting and the High Court sanction.
- Assess the impact of the new debt load (up to ~$3 billion in bridge financing) on H.B. Fuller's leverage ratios once permanent financing is arranged.